双价痢疾结合疫苗

Search documents
北京亦庄经济“含新量”十足,上半年GDP同比增长12.3%
Xin Jing Bao· 2025-08-12 08:37
北京经济技术开发区(简称"北京经开区",也称"北京亦庄")2025年上半年经济数据已"出炉",多项指 标表现亮眼:地区生产总值(GDP)同比增长12.3%;工业总产值突破3400亿元,同比增长15.6%,高 于全市平均增速9.8个百分点;大中型企业研发费用同比增长25.3%,高于全市平均增速21.2个百分点; 信息服务业营业收入、批零业销售额、金融业两项净收入增速均超20%。数据显示,北京亦庄正以科技 创新为核心引擎,加速培育和壮大新质生产力,推动经济"含新量"持续攀升,高质量发展取得新突破。 新产业加速增长,工业增加值占全市比重近四成 上半年,北京亦庄作为北京先进制造业"压舱石"作用愈发凸显,实现产值3478.7亿元,同比增长 15.6%,增速大幅领先全市平均水平9.8个百分点,工业增加值占全市比重37.7%。尤为突出的是,以集 成电路、新能源汽车、新一代信息技术等为代表的新兴产业和以人形机器人、商业航天为代表的未来产 业加速增长,成为驱动区域经济高质量发展的核心引擎。 今年以来,北京亦庄新兴产业和未来产业领域捷报频传,小米汽车累计交付量已突破30万辆;京东方第 6代新型半导体显示器件生产线全面量产;优必选 ...
智飞生物多款重磅疫苗研发取得突破性进展
Jin Rong Jie· 2025-04-08 13:56
Core Viewpoint - The company, Zhifei Biological, has made significant advancements in vaccine development, including a quadrivalent meningococcal vaccine, a therapeutic BCG vaccine for bladder cancer, and a bivalent shigella vaccine, indicating a strategic focus on infectious disease prevention and cancer treatment [1][5]. Group 1: Quadrivalent Meningococcal Vaccine - The quadrivalent meningococcal polysaccharide conjugate vaccine has completed its Phase III clinical trial, demonstrating good immunogenicity and safety, meeting the predefined clinical trial goals [2][5]. - If approved, this vaccine will complement existing meningococcal vaccines, enhancing the company's market position in the meningitis vaccine sector [2][5]. Group 2: Therapeutic BCG Vaccine - The therapeutic BCG vaccine has entered Phase III clinical trials aimed at preventing recurrence in non-muscle invasive bladder cancer patients, with the first subject treated in Hunan Province [3][5]. - This product could become the company's first oncology therapeutic biological product, addressing the high recurrence rates of bladder cancer [3][5]. Group 3: Bivalent Shigella Vaccine - The bivalent shigella vaccine is set to initiate Phase III trials in Bangladesh, targeting bacterial dysentery caused by Shigella flexneri and Shigella sonnei, with the potential to fill a significant market gap as no similar vaccines are currently approved globally [4][5]. - The trial will assess the vaccine's efficacy and safety in infants aged 6 months to 5 years, contributing to the global fight against dysentery, particularly in developing countries [4][5].